-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy ---- Data further reinforce scientific rationale for ATR 1072 targeting the root cause
-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants ---- Initial proof of concept data expected in second half of 2027 --SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc.
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics
SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it
SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --SAN DIEGO, Aug. 13,
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA
SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement
-- ATR 1072 is the company's first precision cardiology program to enter the clinic ---- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for
SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment Inducement
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has
